Dr. David G. Brabham, DO
Cardiology (Cardiovascular Disease Physician)
Who else practices at this address →
Potter County includes primary care (100% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of North Texas Hsc, College of Osteopathic Med (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 1,926
Licensed in Texas since 2007, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: University of North Texas Hsc, College of Osteopathic Med
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
TX license M7869 (first issued 2007; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bsa Hospital Amarillo, TX
- Northwest Texas Hospital Amarillo, TX
- Golden Plains Community Hospital Borger, TX
- Pampa Regional Medical Center Pampa, TX
- Hemphill County Hospital Canadian, TX
Medical groups
- Northwest Texas Healthcare System Inc (22 clinicians)
- Bsa Hospital LLC (21 clinicians)
- Cardiology Center of Amarillo (14 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,926
- Services billed
- 15,630
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 2,619 | 299 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 857 | 101 |
| Established patient office or other outpatient visit, 30-39 minutes | 829 | 683 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 797 | 93 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 608 | 87 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 590 | 450 |
| Injection, regadenoson, 0.1 mg | 464 | 114 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 362 | 360 |
| Nuclear medicine study of heart muscle blood flow by pet | 361 | 359 |
| Heart muscle strain imaging | 249 | 232 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carvedilol Other prescribers in Amarillo, TX | 1,504 |
| Spironolactone Other prescribers in Amarillo, TX | 1,204 |
| Atorvastatin Calcium Other prescribers in Amarillo, TX | 828 |
| Eliquis (apixaban) Other prescribers in Amarillo, TX | 802 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Amarillo, TX | 786 |
| Furosemide Other prescribers in Amarillo, TX | 719 |
| Entresto (sacubitril/valsartan) Other prescribers in Amarillo, TX | 669 |
| Rosuvastatin Calcium Other prescribers in Amarillo, TX | 611 |
| Jardiance (empagliflozin) Other prescribers in Amarillo, TX | 490 |
| Lisinopril Other prescribers in Amarillo, TX | 457 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 39 payments worth $16,006 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $6,740 |
|---|---|
| Cordis US Corp. | $3,675 |
| Bayer HealthCare Pharmaceuticals Inc. | $3,477 |
| Lilly USA, LLC | $1,320 |
| Abbott Laboratories | $471 |
| E.r. Squibb & Sons, L.l.c. | $171 |
| Abiomed | $107 |
| Edwards Lifesciences Corporation | $45.10 |
| Compensation for services other than consulting (speaking, faculty) | $11,252 |
|---|---|
| Consulting Fee | $3,600 |
| Food and Beverage | $1,154 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Cordis US Corp. Oct 17, 2025 | Consulting Fee MYNX CONTROL VENOUS · Cardiology/Vascular Diseases | $3,600 |
| Bayer HealthCare Pharmaceuticals Inc. Dec 5, 2025 | Compensation for services other than consulting (speaking, faculty) Kerendia · Cardio-Renal | $3,317 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Dec 15, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $2,425 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Jul 14, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $1,550 |
| Lilly USA, LLC Feb 24, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · Diabetes | $1,320 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Apr 29, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $880 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $880 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) JARDIANCE · DIABETES | $880 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 9 companies. The companies reported $1,621,081 in research payments for these studies, mostly to the institutions running them.
- Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim International GmbH - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
Janssen Research & Development, LLC - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or O…
Amgen Inc. - A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascula…
Novartis Pharmaceuticals Corporation - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim Pharma GmbH & Co.kg - A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a)…
Novartis Pharmaceuticals Corporation - Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENT…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.